This week

Fourteen peptides cleared the list in February. GHRP-6 didn't.

On June 4, a [Pharmacy Times analysis](https://www.pharmacytimes.com/view/the-peptide-reclassification-everyone-s-talking-about-a-pharmacist-s-take-on-what-rfk-jr-s-announcement-actually-means) of the February 2026 peptide reclassification laid out the scorecard in direct terms: fourteen peptides had returned to Category 1 status, five had not. The free list reads like a comprehensive tour of the biohacker circuit — BPC-157, TB-500, CJC-1295, ipamorelin, AOD-9604, GHK-Cu, semax, selank, KPV, MOTS-c, thymosin alpha-1, and several others. The restricted list that was not resolved: Melanotan II, LL-37, PEG-MGF, GHRP-2, and GHRP-6. As of June 2026, GHRP-6 cannot be legally compounded by 503A pharmacies for clinical use. It is not on the July 23–24 FDA Pharmacy Compounding Advisory Committee agenda, which reviews BPC-157, TB-500, MOTS-c, KPV, emideltide, epitalon, and semax — but not growth hormone secretagogues. The Pharmacy Times pharmacist framing is specific: growth hormone secretagogues including GHRP-6 and GHRP-2 face a different regulatory problem because they overlap with the pharmacology of FDA-approved growth hormone products. That distinction does not appear in the celebratory posts that followed the February announcement.

The actual biology

A ghrelin receptor agonist with a documented appetite consequence

GHRP-6 is a synthetic hexapeptide whose primary mechanism is agonism at the growth hormone secretagogue receptor 1a, more commonly called the ghrelin receptor. When it binds GHSR-1a on somatotroph cells in the anterior pituitary, it drives growth hormone release through a pathway that is distinct from growth hormone releasing hormone analogs like CJC-1295 or sermorelin. That distinction is why early secretagogue research combined GHRH analogs with ghrelin receptor agonists — the two signaling inputs were additive in GH output in human endocrine studies. The pharmacological complication comes from the same receptor. Ghrelin is first an appetite hormone; GHSR-1a agonism at the pituitary is the growth hormone application, but receptor activity throughout the body includes hunger signaling, prolactin-related pathways, and cortisol context. GHRP-6's documented appetite stimulation is not a contaminant effect or a bad batch — it is the expected consequence of the receptor target. [PubMed literature on GHRP-6](https://pubmed.ncbi.nlm.nih.gov/?term=GHRP-6) spans three decades of endocrine and receptor pharmacology, documenting both the GH-stimulating activity and the ghrelin-receptor effects that come with it. The compound ipamorelin was developed partly to address this — its receptor selectivity was designed to minimize the appetite and prolactin signals that older secretagogues like GHRP-6 produced.

What the internet says

Old-school forum favorite, now stuck while the newer versions got out

In gym peptide forums, GHRP-6 has occupied the old-school lane for years. It was one of the first synthetic GH secretagogues widely circulated in bodybuilding communities, before ipamorelin's cleaner receptor profile made it the preferred option for clinics and newer users who wanted GH pulse activity without managing hunger. The stack that appeared most in early forum discussion — a GHRH analog with a GHRP — was often sermorelin or CJC-1295 on one side and GHRP-6 on the other. What February 2026 did to GHRP-6's community position is specific: it put the compound in a gap. The peptides that were stacked with it are now legal to compound again. CJC-1295 and ipamorelin are flowing through prescriptions. BPC-157 is getting a PCAC review date. GHRP-6 — frequently the partner compound in the old stacks — is still restricted, with no review date announced and no pathway open. Online, this has produced angry forum posts framing the continued restriction as regulatory inconsistency. The Pharmacy Times pharmacist analysis did not call it inconsistency. It called it pharmacology: the FDA sees a compound that stimulates GH release in the same lane as approved growth hormone products, and the compounding framework for that compound has not been resolved.

What the data says

Human endocrine data exists, and 2026 research is moving elsewhere

GHRP-6 has human evidence behind it — this is not a forum-only peptide. Published endocrine studies document GH pulse responses in human subjects following GHRP-6 administration, and that is the basis for the Human-supported tier on this page. [ClinicalTrials.gov registrations for GHRP-6](https://clinicaltrials.gov/search?term=GHRP-6) include studies across endocrine stimulation tests and metabolic contexts. The evidence base is narrower than the marketing copy, which is typical for compounds in this class: the endocrine signal is real, and the performance-outcome claims layered on top of it are extrapolations that no trial has confirmed in the performance context. In 2026, the research frontier for GHRP-6 has moved into territory that the compounding community is not generally tracking. A study published this year in Pharmaceuticals examined [GHRP-6 in post-infarct ventricular remodeling](https://doi.org/10.3390/ph19030468), finding cardioprotective effects in a coronary ligation model — a line of work exploring GHRP-6's cytoprotective biology beyond its pituitary application. That direction of research is mechanistically coherent with what the ghrelin receptor does in cardiac tissue. It is also not the gym-recovery or body-composition use case that drives most current search volume. The FDA's decision to keep GHRP-6 on the restricted list is not a verdict on the cardiac research — it is a judgment about the compounding framework in the context of GH-axis pharmacology.

Human-supported — PeptideFactCheck stance

The evidence tier is earned. The regulatory story is a separate problem.

GHRP-6 holds the Human-supported evidence tier on PeptideFactCheck — useful signal, but internet claims may go beyond the data. That tier is calibrated to the endocrine literature: GH response exists, the ghrelin receptor mechanism is established, and some human study coverage is real. What the tier does not address is the regulatory situation, and in June 2026 the two stories are running in different directions. The evidence tier did not change when fourteen peptides were moved to Category 1 in February. The compounding status did. GHRP-6's continued restriction is not a scientific verdict on the peptide's mechanism — it is a regulatory judgment about what it means to compound a ghrelin receptor agonist that stimulates GH release when the FDA has already approved growth hormone products for specific indications. CJC-1295 and ipamorelin work differently on the axis; their pharmacological profile was apparently distinguishable enough from approved products to survive the Category 1 review. GHRP-6 and GHRP-2 were not, and the July PCAC meeting is not going to change that in the next six weeks. The human evidence for GHRP-6 deserves to be read clearly and separately from the access story. The Pharmacy Times scorecard is what it is: fourteen out, five still restricted, and the GH secretagogues that activate the ghrelin receptor directly are in the five.

Editorial boundary

What this page will not do

It will not provide dosing, cycling, sourcing, injection, or personal medical instructions. The job is to classify claims and explain mechanisms.